Neurodegenerative Disease Management presents findings, analysis and commentary in the ongoing battle with this range of debilitating illnesses. The journal provides guidance to the multidisciplinary disease management community regarding the most effective treatment strategies and the implications of cutting-edge research as it emerges.
Topics covered include:
All neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, ALS and multiple sclerosis
Disease mechanisms
Epidemiology
Genetic and environmental influences on disease pathogenesis
Clinical manifestations and diagnosis of disease
Use of biomarkers in diagnosis and prognosis
Use of technology to track symptoms and impact of treatment
Therapeutic options
Evaluation and management of cognitive impairment and dementia
Prospects for new treatments such as cell and gene therapy
Medical treatment guidelines
Adverse events and drug safety
Pharmacoeconomics, outcomes research, real-world evidence and quality of life
Disease management in developed and developing countries
Palliative care
Articles are subject to peer review by three independent referees on a double-blind basis. Authors publishing in the journal are asked to disclose any professional or financial interest that may be perceived as causing a conflict of interest in the context of the article.
The journal welcomes unsolicited article proposals.
Journal metrics
Citation metrics
2.3 (2023) Impact Factor
2.6 (2023) 5 year IF
4.3 (2023) CiteScore (Scopus)
Q2 CiteScore Best Quartile
0.593 (2023) SNIP
0.618 (2023) SJR
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors
who are deciding where to submit their next manuscript for publication.
However, any one metric only tells a part of the story of a journal’s
quality and impact. Each metric has its limitations which means that it
should never be considered in isolation, and metrics should be used to
support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside
other qualitative factors such as a journal’s aims & scope, its
readership, and a review of past content published in the journal. In
addition, a single article should always be assessed on its own merits and
never based on the metrics of the journal it was published in.
Usage and acceptance rate data above are for the last full calendar year
and are updated annually in February. Speed data is updated every six
months, based on the prior six months. Citation metrics are updated
annually mid-year. Please note that some journals do not display all of
the following metrics
(find out why).
Usage:
the total number of times articles in the journal were viewed by users
of Taylor & Francis Online in the previous calendar year, rounded to the
nearest thousand.
Citation Metrics
Impact Factor*:
the average number of citations received by articles published in the
journal within a two-year window. Only journals in the Clarivate Science
Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI),
Arts and Humanities Citation Index (AHCI) and the Emerging Sources
Citation Index (ESCI) have an Impact Factor.
Impact Factor Best Quartile*:
the journal’s highest subject category ranking in the Journal Citation
Reports. Q1 = 25% of journals with the highest Impact Factors.
5 Year Impact Factor*:
the average number of citations received by articles in the journal
within a five-year window.
CiteScore (Scopus)†:
the average number of citations received by articles in the journal over
a four-year period.
CiteScore Best Quartile†:
the journal’s highest CiteScore ranking in a Scopus subject category. Q1
= 25% of journals with the highest CiteScores.
SNIP
(Source Normalized Impact per Paper):
the number of citations per paper in the journal, divided by citation
potential in the field.
SJR
(Scimago Journal Rank):
Average number of (weighted) citations in one year, divided by the
number of articles published in the journal in the previous three years.
Speed/acceptance
From submission to first decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision. Based on manuscripts receiving a
first decision in the last six months.
From submission to first post-review decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision if it is sent out for peer review.
Based on manuscripts receiving a post-review first decision in the last
six months.
From acceptance to online publication:
the average (median) number of days from acceptance of a manuscript to
online publication of the Version of Record. Based on articles published
in the last six months.
Acceptance rate:
articles accepted for publication by the journal in the previous
calendar year as percentage of all papers receiving a final decision.
Theresa A Zesiewicz, University of South Florida, FL, USA Dag Aarsland, King's College London, UK
Editorial Board
Dag Aarsland, King's College London, UK Ammar Al-Chalabi, King's College London, UK Quincy J Almeida, Wilfrid Laurier University, Canada James P Bennett, Jr, Neurodegeneration Therapeutics, Inc., VA, USA Henry Brodaty, University of New South Wales, Australia John Collinge,UCL Institute of Neurology, UK Bradford D Dickerson, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA Alessandro Di Rocco, Northwell Health, NY, USA Tzvi Dwolatzky, Rambam Medical Center, Israel James E Galvin, Florida Atlantic University, FL, USA Donald Grosset, University of Glasgow, UK John Hardy,UCL Institute of Neurology, UK Nobutaka Hattori, Juntendo University School of Medicine, Japan Aleksey Kazantsev, Harvard Medical School, MA, USA Martin Knapp, London School of Economics and Political Science, UK Tom Mercer,Queen Margaret University, UK Erwin B Montgomery, Greenville Neuromodulation Center, PA, USA Karen E Morrison, University of Southampton, UK M. Maral Mouradian, Rutgers University – Robert Wood Johnson Medical School, NJ, USA Ronald C Petersen, Mayo Clinic, MN, USA Olivier Piguet, University of Sydney, Australia Werner Poewe, Medical University Innsbruck, Austria Pamela Shaw, University of Sheffield, UK Hilkka Soininen, University of Eastern Finland, Finland Till Sprenger, DKD Helios Klinik Wiesbaden, Germany Jon Stamford, Cure Parkinson's Trust, UK Eduard Tolosa, Universitat de Barcelona, Spain Joe Verghese, Albert Einstein College of Medicine, NY, USA Nicholas W Wood, UCL Institute of Neurology, UK
Open access
Neurodegenerative Disease Management is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
Increase the discoverability and readership of your article
Make an impact and reach new readers, not just those with easy access to a research library
Freely share your work with anyone, anywhere
Comply with funding mandates and meet the requirements of your institution, employer or funder
Rigorous peer review for every open access article
Article Publishing Charges (APC)
If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors, make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110803/Subject-Sample-2021-Bioscience.jpg"})